TIGIT and acute myeloid leukemia: Results stated an altered presence of TIGIT and CD226 on γδ T cells with an augment in TIGIT+ γδ T cells and a reduction in CD226+ γδ T cells in de novo AML subjects, while TIGIT− CD226+ γδ T cells were reinstated in AML subjects who attained a complete response after treatment.